A. Cohn

发表

Abstract LB-121: Randomized phase II study of the efficacy and safety of gemcitabine + TH-302 (G+T) vs gemcitabine (G) alone in previously untreated patients with advanced pancreatic cancer

M. Borad, D. Ryan, S. Kroll, 2012 .

A randomized phase IIIB trial of chemotherapy, bevacizumab, and panitumumab compared with chemotherapy and bevacizumab alone for metastatic colorectal cancer.

Seta Shahin, J. Hecht, J. Marshall, 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

External beam irradiation and the combination of cisplatin and carmustine followed by carmustine alone for the treatment of high‐grade glioma

M. Berger, K. Stelzer, R. Livingston, 2008, Cancer.

Risk factors for gastrointestinal perforations in patients with metastatic colorectal cancer receiving bevacizumab plus chemotherapy.

J. Hainsworth, A. Grothey, S. Sarkar, 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Results of a phase II trial of cetuximab plus capecitabine/irinotecan as first-line therapy for patients with advanced and/or metastatic colorectal cancer.

T. Cartwright, A. Cohn, S. Vukelja, 2008, Clinical colorectal cancer.

Treatment patterns and clinical outcomes in patients with metastatic colorectal cancer initially treated with FOLFOX-bevacizumab or FOLFIRI-bevacizumab: results from ARIES, a bevacizumab observational cohort study.

A. Grothey, H. Hurwitz, T. Bekaii-Saab, 2012, The oncologist.

Ramucirumab versus placebo in combination with second-line FOLFIRI in patients with metastatic colorectal carcinoma that progressed during or after first-line therapy with bevacizumab, oxaliplatin, and a fluoropyrimidine (RAISE): a randomised, double-blind, multicentre, phase 3 study.

E. Van Cutsem, J. Tabernero, Tae Won Kim, 2015, The Lancet. Oncology.

Biomarker analysis beyond angiogenesis: RAS/RAF mutation status, tumour sidedness, and second-line ramucirumab efficacy in patients with metastatic colorectal carcinoma from RAISE—a global phase III study

E. Van Cutsem, J. Tabernero, A. Grothey, 2018, Annals of oncology : official journal of the European Society for Medical Oncology.

Exposure–response relationship of ramucirumab in patients with advanced second-line colorectal cancer: exploratory analysis of the RAISE trial

E. Van Cutsem, J. Tabernero, V. Heinemann, 2017, Cancer Chemotherapy and Pharmacology.

Subgroup analysis in RAISE: a randomized, double-blind phase III study of irinotecan, folinic acid, and 5-fluorouracil (FOLFIRI) plus ramucirumab or placebo in patients with metastatic colorectal carcinoma progression†

E. Van Cutsem, J. Tabernero, T. Ciuleanu, 2016, Annals of oncology : official journal of the European Society for Medical Oncology.

Safety and effectiveness of bevacizumab treatment for metastatic colorectal cancer: final results from the Avastin(®) Registry - Investigation of Effectiveness and Safety (ARIES) observational cohort study.

A. Grothey, H. Hurwitz, T. Bekaii-Saab, 2014, Clinical oncology (Royal College of Radiologists (Great Britain)).

An open-label clinical trial evaluating safety and pharmacokinetics of two dosing schedules of panitumumab in patients with solid tumors.

J. Crawford, H. Burris, R. Cohen, 2009, Clinical colorectal cancer.

Phase II study of oral capecitabine in patients with advanced or metastatic pancreatic cancer.

T. Szatrowski, T. Cartwright, J. Cox, 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Phase I I S tudy o f O ral C apecitabine i n P atients W ith Advanced o r M etastatic P ancreatic C ancer

T. Szatrowski, T. Cartwright, J. Cox, 2002 .

Bevacizumab exposure beyond first disease progression in patients with metastatic colorectal cancer: analyses of the ARIES observational cohort study

A. Grothey, H. Hurwitz, T. Bekaii-Saab, 2014, Pharmacoepidemiology and drug safety.

Ramucirumab combined with FOLFOX as front-line therapy for advanced esophageal, gastroesophageal junction, or gastric adenocarcinoma: a randomized, double-blind, multicenter Phase II trial.

P. Philip, S. Alberts, Z. Wainberg, 2016, Annals of oncology : official journal of the European Society for Medical Oncology.

Phase I study of dasatinib in combination with capecitabine, oxaliplatin and bevacizumab followed by an expanded cohort in previously untreated metastatic colorectal cancer

S. McCall, H. Hurwitz, G. Blobe, 2014, Investigational New Drugs.

Clinical outcomes in bevacizumab (BV)-treated patients (pts) with metastatic colorectal cancer (mCRC): Results from ARIES observational cohort study (OCS) and confirmation of BRiTE data on BV beyond progression (BBP).

A. Grothey, H. Hurwitz, T. Bekaii-Saab, 2010 .

Efficacy of bevacizumab plus chemotherapy as first-line treatment of patients with metastatic colorectal cancer: Updated results from a large observational registry in the US (BRiTE).

J. Hainsworth, A. Grothey, P. Flynn, 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Randomized, double‐blind, phase two study of ruxolitinib plus regorafenib in patients with relapsed/refractory metastatic colorectal cancer

J. Nemunaitis, J. Bendell, C. Borg, 2018, Cancer medicine.

Results of the X-PECT study: A phase III randomized double-blind, placebo-controlled study of perifosine plus capecitabine (P-CAP) versus placebo plus capecitabine (CAP) in patients (pts) with refractory metastatic colorectal cancer (mCRC).

N. Senzer, J. Bendell, A. Lockhart, 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Activity of cetuximab in patients with colorectal cancer refractory to both irinotecan and oxaliplatin.

E. Van Cutsem, R. Mayer, H. Lenz, 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Use of Transarterial Chemoembolization (TACE) and Sorafenib in Patients with Unresectable Hepatocellular Carcinoma: US Regional Analysis of the GIDEON Registry

J. Geschwind, Robert C. G. Martin, A. Cohn, 2015, Liver Cancer.

A Multicenter, Phase I, Dose-Escalation Study to Assess the Safety, Tolerability, and Pharmacokinetics of Etirinotecan Pegol in Patients with Refractory Solid Tumors

M. Borad, D. V. Von Hoff, G. Weiss, 2012, Clinical Cancer Research.

Phase III trial of cetuximab, bevacizumab, and 5-fluorouracil/leucovorin vs. FOLFOX-bevacizumab in colorectal cancer.

D. Solit, E. Vakiani, L. Saltz, 2012, Clinical colorectal cancer.

A phase II study of pemetrexed in patients with advanced hepatocellular carcinoma

A. Cohn, L. Asmar, S. Nicol, 2008, Investigational New Drugs.

TRAIL receptor agonist conatumumab with modified FOLFOX6 plus bevacizumab for first‐line treatment of metastatic colorectal cancer

L. Saltz, F. Galimi, V. Haddad, 2013, Cancer.

Safety of bevacizumab (BV) among patients (pts) receiving first-line chemotherapy (CT) for metastatic colorectal cancer (mCRC): Preliminary results from a larger registry in the U.S

R. Robles, A. Grothey, F. Kabbinavar, 2005 .

A Phase II Randomized Trial (GO27827) of First-Line FOLFOX Plus Bevacizumab with or Without the MET Inhibitor Onartuzumab in Patients with Metastatic Colorectal Cancer.

H. Koeppen, L. Hart, J. Bendell, 2017, The oncologist.

CSF1 receptor inhibition of tenosynovial giant cell tumor using novel disease-specific MRI measures of tumor burden.

G. Shapiro, C. Peterfy, I. Puzanov, 2022, Future oncology.

Results from Phase I Extension Study Assessing Pexidartinib Treatment in Six Cohorts with Solid Tumors including TGCT, and Abnormal CSF1 Transcripts in TGCT

G. Shapiro, C. Peterfy, I. Puzanov, 2021, Clinical Cancer Research.

Structure-Guided Blockade of CSF1R Kinase in Tenosynovial Giant-Cell Tumor.

M. van de Rijn, G. Shapiro, C. Peterfy, 2015, The New England journal of medicine.

SPIRITT (study 20060141): A randomized phase II study of FOLFIRI with either panitumumab (pmab) or bevacizumab (bev) as second-line treatment (tx) in patients (pts) with wild-type (WT) KRAS metastatic colorectal cancer (mCRC).

J. Hecht, S. Dakhil, W. Go, 2013 .

Efficacy and Safety of Atezolizumab Plus Bevacizumab Following Disease Progression on Atezolizumab or Sunitinib Monotherapy in Patients with Metastatic Renal Cell Carcinoma in IMmotion150: A Randomized Phase 2 Clinical Trial.

J. Reeves, A. Ravaud, J. Hainsworth, 2021, European urology.

Lenvatinib plus pembrolizumab in patients with advanced endometrial cancer: an interim analysis of a multicentre, open-label, single-arm, phase 2 trial.

E. Schmidt, D. Hyman, D. Rasco, 2019, The Lancet. Oncology.

Initial results from ARIES, a multi-indication bevacizumab (BV) observational cohort study (OCS): Characteristics of metastatic colorectal cancer (mCRC) patients (pts) receiving BV and chemotherapy (CT) in 2nd line

D. Sargent, A. Grothey, T. Bekaii-Saab, 2008 .

Activity of cabozantinib (XL184) in hepatocellular carcinoma patients (pts): Results from a phase II randomized discontinuation trial (RDT).

E. Van Cutsem, C. Verslype, D. Ramies, 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Phase II trial of lenvatinib (LEN) plus pembrolizumab (PEMBRO) for disease progression after PD-1/PD-L1 immune checkpoint inhibitor (ICI) in metastatic clear cell renal cell carcinoma (mccRCC).

R. Motzer, J. Hsieh, E. Schmidt, 2020 .

Single-arm, phase 2 study of regorafenib plus nivolumab in patients with mismatch repair-proficient (pMMR)/microsatellite stable (MSS) colorectal cancer (CRC).

N. Sharma, M. Fakih, J. Bendell, 2021 .

Panitumumab (pmab) regimen evaluation in colorectal cancer to estimate primary response to treatment (PRECEPT): Effect of KRAS mutation status on second-line treatment (tx) with pmab and FOLFIRI

David A. Smith, R. Sikorski, M. Yassine, 2008 .

Docetaxel plus oxaliplatin with or without fluorouracil or capecitabine in metastatic or locally recurrent gastric cancer: a randomized phase II study.

C. Boni, E. Van Cutsem, J. Tabernero, 2015, Annals of oncology : official journal of the European Society for Medical Oncology.

279 Correlation of acne rash and tumor response with cetuximab monotherapy in patients with colorectal cancer refractory to both irinotecan and oxaliplatin

R. Mayer, H. Lenz, E. Cutsem, 2004 .

Effectiveness and safety of second-line (2L) irinotecan- and oxaliplatin-based regimens after first-line (1L) bevacizumab (BV)-containing treatment (tx) for metastatic colorectal cancer (mCRC): Results from the ARIES observational cohort study.

A. Grothey, H. Hurwitz, T. Bekaii-Saab, 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Analysis of EGFR status in metastatic colorectal cancer patients treated with cetuximab monotherapy

R. Mayer, H. Lenz, E. Cutsem, 2005 .

Consistent response to treatment with cetuximab monotherapy in patients with metastatic colorectal cancer

H. Lenz, R. Mayer, E. Cutsem, 2005 .

D04Exposure-response (E-R) relationship of Ramucirumab (RAM) from a global, randomized, double-blind, Phase 3 study of patients (Pts) with advanced 2nd line colorectal cancer

J. Tabernero, T. Ciuleanu, G. Bodoky, 2016 .

2123 Exposure-response (E-R) relationship of Ramucirumab (RAM) from a global, randomized, double-blind, Phase 3 study of patients (Pts) with advanced 2nd line colorectal cancer

J. Tabernero, T. Ciuleanu, G. Bodoky, 2015 .

Lenvatinib (LEN) plus pembrolizumab (PEMBRO) for early-line treatment of advanced/recurrent endometrial cancer (EC).

E. Schmidt, J. Mier, C. Aghajanian, 2020 .

Correction to: 33rd Annual Meeting & Pre-Conference Programs of the Society for Immunotherapy of Cancer (SITC 2018)

J. Taube, S. Jain, E. Schmidt, 2019, Journal of Immunotherapy for Cancer.

Hematologic response to three alternative dosing schedules of azacitidine in patients with myelodysplastic syndromes.

J. Hainsworth, T. Cosgriff, A. Cohn, 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Ramucirumab (RAM) plus FOLFOX as front-line therapy (Rx) for advanced gastric or esophageal adenocarcinoma (GE-AC): Randomized, double-blind, multicenter phase 2 trial.

P. Philip, S. Alberts, Z. Wainberg, 2014 .

Melatonin therapy of advanced human malignant melanoma

R. Gonzalez, A. Cohn, W. Robinson, 1991, Melanoma research.

Results of a phase II trial of cetuximab+XELIRI as first-line therapy of patients with advanced and/or metastatic colorectal cancer.

T. Cartwright, A. Cohn, L. Asmar, 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

A randomized, placebo-controlled, double blind, multicenter phase II adjuvant trial of the efficacy, immunogenicity, and safety of GI-4000 plus gem versus gem alone in patients with resected pancreas cancer with activating RAS mutations/survival and immunology analysis of the R1 subgroup.

F. Harrell, W. Fisher, A. Rosemurgy, 2012 .

An Open Label Trial of Sustained-release Cytarabine (DepoCyt™) for the Intrathecal Treatment of Solid Tumor Neoplastic Meningitis

M. Gilbert, W. Mason, E. Wong, 2004, Journal of Neuro-Oncology.

Evaluation of cell-free DNA approaches for multi-cancer early detection.

D. Berry, T. Yeatman, E. Fung, 2022, Cancer cell.

Safety and efficacy of oxaliplatin and fluoropyrimidine regimens with or without bevacizumab as first-line treatment of metastatic colorectal cancer: results of the TREE Study.

J. Hainsworth, L. Hart, L. Fehrenbacher, 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Intrathecal treatment of neoplastic meningitis due to breast cancer with a slow-release formulation of cytarabine

L. Recht, M. Gilbert, W. Mason, 2001, British Journal of Cancer.

A phase II study of milataxel: a novel taxane analogue in previously treated patients with advanced colorectal cancer

J. Picus, A. Lockhart, D. Berg, 2008, Cancer Chemotherapy and Pharmacology.

Clinical validation of a targeted methylation-based multi-cancer early detection test using an independent validation set.

C. Swanton, E. Klein, D. Cosgrove, 2021, Annals of oncology : official journal of the European Society for Medical Oncology.

Lenvatinib Plus Pembrolizumab in Patients With Advanced Endometrial Cancer

E. Schmidt, J. Mier, C. Aghajanian, 2020, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

A randomized phase II trial of CRLX101 in combination with bevacizumab versus standard of care in patients with advanced renal cell carcinoma

R. Figlin, R. Motzer, M. Voss, 2017, Annals of oncology : official journal of the European Society for Medical Oncology.

Panitumumab in combination with cytotoxic chemotherapy for the treatment of metastatic colorectal carcinoma.

C. Köhne, J. Douillard, M. Peeters, 2012, Clinical colorectal cancer.

Multicenter phase II and translational study of cetuximab in metastatic colorectal carcinoma refractory to irinotecan, oxaliplatin, and fluoropyrimidines.

E. Van Cutsem, H. Lenz, Z. Tsuchihashi, 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

A randomized phase II trial of CRLX101 in combination with bevacizumab versus standard of care in patients with advanced renal cell carcinoma.

R. Figlin, R. Motzer, M. Voss, 2017 .

Infigratinib in patients with advanced cholangiocarcinoma with FGFR2 gene fusions/translocations: the PROOF 301 trial.

S. Roychowdhury, A. Lamarca, I. Borbath, 2020, Future oncology.

A phase I dose-escalation study to a predefined dose of a transforming growth factor-β1 monoclonal antibody (TβM1) in patients with metastatic cancer

M. Farmen, A. Cleverly, A. Cohn, 2014, International journal of oncology.

A Phase Ib/II Study of Lenvatinib and Pembrolizumab in Advanced Endometrial Carcinoma (Study 111/KEYNOTE-146): Long-Term Efficacy and Safety Update

E. Schmidt, C. Aghajanian, M. Brose, 2023, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Lenvatinib (LEN) and pembrolizumab (PEMBRO) in advanced endometrial cancer (EC)

E. Schmidt, J. Mier, C. Aghajanian, 2019, Annals of Oncology.

Oncotargets and Therapy Dovepress

Fei Liu, Jun Liu, I. Puzanov, 2022 .

Impact of a commercial reference laboratory test recurrence score on decision making in early-stage breast cancer.

A. Cohn, R. Oratz, S. Sedlacek, 2007, Journal of oncology practice.

Cabozantinib in hepatocellular carcinoma: results of a phase 2 placebo-controlled randomized discontinuation study

E. Van Cutsem, R. Kelley, C. Verslype, 2017, Annals of oncology : official journal of the European Society for Medical Oncology.

An open-label, single-arm, phase 2 trial of panitumumab plus FOLFIRI as second-line therapy in patients with metastatic colorectal cancer.

David A. Smith, M. Yassine, A. Cohn, 2011, Clinical colorectal cancer.

Docetaxel or pemetrexed with or without cetuximab in recurrent or progressive non-small-cell lung cancer after platinum-based therapy: a phase 3, open-label, randomised trial.

Edward S. Kim, S. Saxman, L. Schwartzberg, 2013, The Lancet. Oncology.

A Phase 2 Randomized Placebo-Controlled Adjuvant Trial of GI-4000, a Recombinant Yeast Expressing Mutated RAS Proteins in Patients with Resected Pancreas Cancer

F. Harrell, T. Bekaii-Saab, W. Fisher, 2021, Journal of pancreatic cancer.

A phase II clinical and pharmacokinetic study of intravenous exatecan mesylate (DX-8951f) in patients with untreated metastatic gastric cancer

J. Ajani, C. Takimoto, C. Becerra, 2005, Investigational New Drugs.

A Randomized, Phase II Trial of Cetuximab With or Without PX-866, an Irreversible Oral Phosphatidylinositol 3-Kinase Inhibitor, in Patients With Metastatic Colorectal Carcinoma.

A. Jimeno, L. Nabell, D. Bowles, 2016, Clinical colorectal cancer.

Safety of bevacizumab plus chemotherapy as first-line treatment of patients with metastatic colorectal cancer: Updated results from a large observational registry in the US (BRiTE).

J. Hainsworth, A. Grothey, P. Flynn, 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Results of docetaxel plus oxaliplatin (DOCOX) ± cetuximab in patients with metastatic gastric and/or gastroesophageal junction adenocarcinoma: results of a randomised Phase 2 study.

L. I. Hecker, A. Spira, A. Cohn, 2013, European journal of cancer.

Regorafenib plus nivolumab in patients with mismatch repair-proficient/microsatellite stable metastatic colorectal cancer: a single-arm, open-label, multicentre phase 2 study.

B. Ploeger, N. Sharma, M. Fakih, 2023, EClinicalMedicine.

SPIRITT: A Randomized, Multicenter, Phase II Study of Panitumumab with FOLFIRI and Bevacizumab with FOLFIRI as Second-Line Treatment in Patients with Unresectable Wild Type KRAS Metastatic Colorectal Cancer.

J. Hecht, S. Dakhil, W. Go, 2015, Clinical colorectal cancer.

Lenvatinib plus pembrolizumab in patients with either treatment-naive or previously treated metastatic renal cell carcinoma (Study 111/KEYNOTE-146): a phase 1b/2 study.

S. Jain, R. Motzer, J. Hsieh, 2021, The Lancet. Oncology.

Bevacizumab (BV) plus chemotherapy (CT) in second-line metastatic colorectal cancer (mCRC): Initial results from ARIES, a second BV observational cohort study (OCS).

A. Grothey, H. Hurwitz, T. Bekaii-Saab, 2010 .

Randomized Phase II Trial of Gemcitabine Plus TH-302 Versus Gemcitabine in Patients With Advanced Pancreatic Cancer.

M. Borad, D. Ryan, S. Kroll, 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Correction to Lancet Oncol 2015; 16: 499-508. Ramucirumab versus placebo in combination with second-line FOLFIRI in patients with metastatic colorectal carcinoma that progressed during or after first-line therapy with bevacizumab, oxaliplatin, and a fluoropyrimidine (RAISE): a randomised, double-bli

J. Tabernero, A. Cohn, Y. Takayuki, 2015, The Lancet Oncology.

Analysis of angiogenesis biomarkers for ramucirumab efficacy in patients with metastatic colorectal cancer from RAISE, a global, randomized, double-blind, phase III study

E. Van Cutsem, J. Tabernero, T. Ciuleanu, 2017, Annals of oncology : official journal of the European Society for Medical Oncology.

Activity of cabozantinib (XL184) in hepatocellular carcinoma: Results from a phase II randomized discontinuation trial (RDT)

E. Van Cutsem, R. Kelley, C. Verslype, 2012 .

Low‐dose α‐interferon treatment of chronic myeloid leukemia

A. Cohn, R. Gonzalez, W. Robinson, 1992 .

A randomized phase II study comparing mFOLFOX-6 combined with axitinib or bevacizumab or both in patients with metastatic colorectal cancer (mCRC).

J. Hamm, J. Infante, W. Edenfield, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

A randomized, placebo-controlled phase 2 study of ganitumab or conatumumab in combination with FOLFIRI for second-line treatment of mutant KRAS metastatic colorectal cancer.

R. Loberg, J. Tabernero, S. Choo, 2013, Annals of oncology : official journal of the European Society for Medical Oncology.

A. Grothey, H. Hurwitz, T. Bekaii-Saab, 2011, Journal of Clinical Oncology.

Effectiveness of first- or second-line bevacizumab (BV) treatment (tx) in elderly patients (pts) with metastatic colorectal cancer (mCRC) in ARIES, an observational cohort study (OCS).

A. Grothey, H. Hurwitz, T. Bekaii-Saab, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Multicenter, randomized, double‐blind phase 2 trial of FOLFIRI with regorafenib or placebo as second‐line therapy for metastatic colorectal cancer

T. Ryan, R. Goldberg, A. Ivanova, 2018, Cancer.

Current practices in the management of adverse events associated with targeted therapies for advanced renal cell carcinoma: a national survey of oncologists.

M. Lacouture, M. Ewer, V. R. Belum, 2014, Clinical genitourinary cancer.

354 Lenvatinib and pembrolizumab in advanced endometrial carcinoma (EC): long-term efficacy and safety update from a phase 1b/2 study

E. Schmidt, Jie Huang, C. Aghajanian, 2021, Journal for ImmunoTherapy of Cancer.

Editorial : Gene Expression Profile Assays As an Aid in Treatment Decision Making in Early-Stage Breast Cancer

A. Cohn, R. Oratz, S. Sedlacek, 2007 .

Docetaxel plus oxaliplatin with or without fluorouracil or capecitabine in metastatic or locally recurrent gastric cancer: a randomized phase II study.

C. Boni, E. Van Cutsem, J. Tabernero, 2015, Annals of oncology : official journal of the European Society for Medical Oncology.

Whole Recombinant Saccharomyces cerevisiae Yeast Expressing Ras Mutations as Treatment for Patients With Solid Tumors Bearing Ras Mutations: Results From a Phase 1 Trial

D. Bellgrau, M. Morse, B. O'Neil, 2018, Journal of immunotherapy.

Phase Ib/II study of cancer stem cell (CSC) inhibitor BBI608 combined with paclitaxel in advanced gastric and gastroesophageal junction (GEJ) adenocarcinoma.

H. Lenz, T. Bekaii-Saab, S. Mikhail, 2015 .

A randomized, double-blind, phase II study of first-line FOLFOX plus bevacizumab with onartuzumab versus placebo in patients with metastatic colorectal cancer (mCRC).

L. Hart, J. Bendell, D. Shames, 2015 .

Use of staging and scoring systems in hepatocellular carcinoma (HCC): Lessons from U.S. regional analysis of the GIDEON registry.

J. Geschwind, A. El-Khoueiry, A. Venook, 2014 .

Lenvatinib + pembrolizumab in patients with advanced endometrial cancer: Updated results.

E. Schmidt, D. Rasco, C. Aghajanian, 2018 .

Results from panitumumab (pmab) regimen evaluation in colorectal cancer to estimate primary response to treatment (PRECEPT): Second-line treatment with pmab and FOLFIRI by tumor KRAS status.

M. Yassine, A. Cohn, M. Neubauer, 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Axitinib and/or bevacizumab with modified FOLFOX‐6 as first‐line therapy for metastatic colorectal cancer: A randomized phase 2 study

J. Hamm, J. Infante, W. Edenfield, 2013, Cancer.

A phase 1b/2 trial of lenvatinib plus pembrolizumab in patients with squamous cell carcinoma of the head and neck.

E. Schmidt, D. Rasco, M. Brose, 2018 .

Open-label phase II/III study of nivolumab plus standard of care versus standard of care for first-line treatment of metastatic colorectal cancer: Checkmate-9X8.

H. Lenz, J. Tabernero, J. Bendell, 2019, Journal of Clinical Oncology.

Sorafenib use for recurrent hepatocellular cancer after resection or transplantation: Observations from a US regional analysis of the GIDEON registry.

Robert C. G. Martin, J. Geschwind, A. Sanyal, 2017, American journal of surgery.

A multi-center, randomized, double-blind phase II trial of FOLFIRI + regorafenib or placebo for patients with metastatic colorectal cancer who failed one prior line of oxaliplatin-containing therapy

T. Ryan, R. Goldberg, A. Ivanova, 2016 .

BBI608-503-103HCC: A phase Ib/II clinical study of napabucasin (BBI608) in combination with sorafenib or amcasertib (BBI503) in combination with sorafenib (Sor) in adult patients with hepatocellular carcinoma (HCC).

A. El-Khoueiry, B. El-Rayes, F. Braiteh, 2017 .

A deep learning approach for cancer diagnosis exclusively from raw sequencing fragments of bisulfite-treated plasma cell-free DNA

Chao Zhang, X. Shen, Xiangchun Li, 2023, medRxiv.

570 Cabozantinib plus atezolizumab in advanced head and neck cancer previously treated with platinum-containing chemotherapy: Results from cohort 17 of the COSMIC-021 study

A. Santoro, S. Arnold, S. Rottey, 2022, Regular and Young Investigator Award Abstracts.

Sensitive and specific multi-cancer detection and localization using methylation signatures in cell-free DNA

D. Berry, S. Cummings, E. Fung, 2020, Annals of oncology : official journal of the European Society for Medical Oncology.

O-020Quality-of-life results from RAISE: randomized, double-blind phase III study of FOLFIRI plus ramucirumab or placebo in patients with metastatic colorectal carcinoma after first-line therapy with bevacizumab, oxaliplatin, and a fluoropyrimidine

T. Ciuleanu, G. Bodoky, P. Rougier, 2015 .

Abstract A28: Immune responses to mutated Ras - development of a yeast-based immunotherapeutic

Zhimin Guo, C. Coeshott, A. Cohn, 2014 .

Perforation of the great vessels during central venous line placement.

J. D. Armstrong, K. Garg, A. Cohn, 1995, Archives of internal medicine.

Lenvatinib plus pembrolizumab in patients with advanced endometrial cancer: Final analysis of a multicentre, open-label, single-arm, phase 2 trial

D. Rasco, C. Aghajanian, M. Brose, 2020, Gynecologic Oncology.

Activity of Cabozantinib (XL184) in Hepatocellular Carcinoma (HCC) Patients: Results From a Phase 2 Randomized Discontinuation Trial (RDT)

R. Kelley, C. Verslype, D. Ramies, 2012 .

Treatment of Ras mutation-bearing solid tumors using whole recombinant S. cerevisiae yeast expressing mutated Ras: Preliminary safety and immunogenicity results from a phase 1 trial

D. Bellgrau, M. Morse, S. Munson, 2005 .

Phase Ib of anticancer stem cell antibody OMP-59R5 (anti-Notch2/3) in combination with nab-paclitaxel and gemcitabine (Nab-P+Gem) in patients (pts) with untreated metastatic pancreatic cancer (mPC).

L. Smith, J. Bendell, J. Dupont, 2014 .

BRAFV600 mutations in solid tumors, other than metastatic melanoma and papillary thyroid cancer, or multiple myeloma: a screening study

I. Puzanov, A. Cohn, T. Riehl, 2017, OncoTargets and therapy.

BRAF V600 mutations in solid tumors, other than metastatic melanoma and papillary thyroid cancer, or multiple myeloma: a screening study

I. Puzanov, A. Cohn, T. Riehl, 2022 .

Docetaxel or pemetrexed with or without cetuximab in recurrent or progressive non-small-cell lung cancer after platinum-based therapy: a phase 3, open-label, randomised trial.

Edward S. Kim, S. Saxman, L. Schwartzberg, 2013, The Lancet. Oncology.

Structure-Guided Blockade of CSF1R Kinase in Tenosynovial Giant-Cell Tumor.

M. van de Rijn, G. Shapiro, C. Peterfy, 2015, The New England journal of medicine.

Phase III trial of cetuximab, bevacizumab, and 5-fluorouracil/leucovorin vs. FOLFOX-bevacizumab in colorectal cancer.

D. Solit, E. Vakiani, L. Saltz, 2012, Clinical colorectal cancer.

3049 POSTER Management of hypertension (HTN) in patients (pts) with metastatic colorectal cancer (mCRC) treated with bevacizumab (BV) plus chemotherapy (CT)

J. Hainsworth, A. Grothey, J. Yi, 2007 .

Multiple splenic lymphoid cell subpopulations regulate H-2 antigen expression on teratocarcinoma cells in vivo.

J. Sandoz, S. Ostrand-Rosenberg, A. Cohn, 1983, Journal of immunology.

Efficacy/safety analysis of a phase 2 study of ruxolitinib (Rux) + regorafenib (Re) in patients (pts) with relapsed/refractory (r/r) metastatic colorectal cancer (mCRC).

J. Nemunaitis, J. Bendell, C. Borg, 2017 .

Safety summary of panitumumab (pmab) in combination with chemotherapy (ctx) from four clinical trials in patients (pts) with metastatic colorectal cancer (mCRC).

J. Douillard, M. Peeters, T. Price, 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

P PROGNOSIS IMPACT OF POSTOPERATIVE RADIATION IN PATIENTS WITH RADICAL ESOPHAGECTOMY AND PATHOLOGIC LYMPH NODES POSITIVE ESOPHAGEAL CANCER

J. Reis-Filho, M. Borad, D. Ryan, 2012 .

1123O Evaluation of cell-free DNA approaches for multi-cancer early detection

T. Yeatman, E. Hubbell, Minetta C. Liu, 2021, Annals of Oncology.